Laura Mariën
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Mariën has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Timon Vandamme
Department of Oncology Antwerp University Hospital Edegem Belgium
9 shared publications Willem Lybaert
NETwerk–ENETS Center of Excellence Antwerp‐Waasland Belgium
9 shared publicationsGuy Van Camp
Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, 2610, Belgium; Center for Oncological Research, Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Antwerp, 2610, Belgium
8 shared publicationsKen Op de Beeck
Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, 2610, Belgium; Center for Oncological Research, Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Antwerp, 2610, Belgium
8 shared publications- Marc Peeters
Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium
8 shared publications Bart Op de Beeck
7 shared publications
Latest Publications
- 12 November 2026
- Published by University of Antwerp
From germline genetics to the epigenome : complementary approaches to the molecular characterization of neuroendocrine neoplasms
Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of tumors that arise throughout the body and differ markedly in hormonal activity, molecular background, and clinical outcome. This thesis focused on well-differentiated neuroendocrine tumors (NETs) and addressed two clinically relevant challenges: recognizing inherited predisposition and the timely detection of tumor activity once disease is suspected or present. In the first part of this thesis, we investigated the recognition of inherited predisposition in NET care. A 12-year retrospective study within NETwerk, a Belgian ENETS Center of Excellence, assessed MEN1 testing in patients diagnosed with pancreatic, pulmonary, gastric, or thymic NET before the age of 70. Testing showed moderate agreement with guideline-based indications (κ = 0.50, p<0.001), while incomplete phenotyping and documentation limited risk assessment. To explore hereditary risk beyond classical NEN predisposition syndromes, we investigated gastrointestinal manifestation in Jervell and Lange-Nielsen syndrome (JLNS). By combining two newly identified families with previously reported cases, we found that biallelic KCNQ1 loss-of-function was associated with sustained hypergastrinemia and gastric cancer, including NENs. These findings highlight the importance of systematic clinical phenotyping to guide genetic testing and surveillance. The second part of this thesis explored DNA methylation as a source of biological insight and potential biomarkers for improved NET detection. Genome-wide methylation analysis of 439 pancreatic, small intestinal, and lung NETs, and 6,894 controls revealed shared and subtype-specific methylation patterns. Support Vector Machine (SVM)-based ranking identified differentially methylated regions with high relative discriminative potential, supporting its use as biomarkers. To further investigate the potential of targeted methylation-based biomarkers, we developed NET-IMPRESS, a targeted, bisulfite-free assay for circulating tumor DNA (ctDNA) detection in plasma. In patients with metastatic NETs, NET-IMPRESS achieved an area under the curve of 0.82 and an average precision of 0.90. We detected ctDNA in patients with normal chromogranin A levels and identified additional patients missed by copy-number alteration analysis, including patients with lower-grade and lung NETs. Finally, a mixed-methods study of 195 cancer patients explored perspectives on ctDNA-based testing. Although knowledge of liquid biopsy was limited, patients were generally receptive when clinical validity was assumed. Acceptance was driven by perceived clinical benefit, trust in clinicians, clear communication, emotional reassurance, and the possibility of reducing follow-up burden. Ultimately, this thesis moves NET care closer to a future in which inherited risk is recognized more consistently, tumor activity is monitored less invasively, and clinical decisions are increasingly guided by individual disease biology.
- 12 November 2026
- Published by University of Antwerp
From germline genetics to the epigenome : complementary approaches to the molecular characterization of neuroendocrine neoplasms
Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of tumors that arise throughout the body and differ markedly in hormonal activity, molecular background, and clinical outcome. This thesis focused on well-differentiated neuroendocrine tumors (NETs) and addressed two clinically relevant challenges: recognizing inherited predisposition and the timely detection of tumor activity once disease is suspected or present. In the first part of this thesis, we investigated the recognition of inherited predisposition in NET care. A 12-year retrospective study within NETwerk, a Belgian ENETS Center of Excellence, assessed MEN1 testing in patients diagnosed with pancreatic, pulmonary, gastric, or thymic NET before the age of 70. Testing showed moderate agreement with guideline-based indications (κ = 0.50, p<0.001), while incomplete phenotyping and documentation limited risk assessment. To explore hereditary risk beyond classical NEN predisposition syndromes, we investigated gastrointestinal manifestation in Jervell and Lange-Nielsen syndrome (JLNS). By combining two newly identified families with previously reported cases, we found that biallelic KCNQ1 loss-of-function was associated with sustained hypergastrinemia and gastric cancer, including NENs. These findings highlight the importance of systematic clinical phenotyping to guide genetic testing and surveillance. The second part of this thesis explored DNA methylation as a source of biological insight and potential biomarkers for improved NET detection. Genome-wide methylation analysis of 439 pancreatic, small intestinal, and lung NETs, and 6,894 controls revealed shared and subtype-specific methylation patterns. Support Vector Machine (SVM)-based ranking identified differentially methylated regions with high relative discriminative potential, supporting its use as biomarkers. To further investigate the potential of targeted methylation-based biomarkers, we developed NET-IMPRESS, a targeted, bisulfite-free assay for circulating tumor DNA (ctDNA) detection in plasma. In patients with metastatic NETs, NET-IMPRESS achieved an area under the curve of 0.82 and an average precision of 0.90. We detected ctDNA in patients with normal chromogranin A levels and identified additional patients missed by copy-number alteration analysis, including patients with lower-grade and lung NETs. Finally, a mixed-methods study of 195 cancer patients explored perspectives on ctDNA-based testing. Although knowledge of liquid biopsy was limited, patients were generally receptive when clinical validity was assumed. Acceptance was driven by perceived clinical benefit, trust in clinicians, clear communication, emotional reassurance, and the possibility of reducing follow-up burden. Ultimately, this thesis moves NET care closer to a future in which inherited risk is recognized more consistently, tumor activity is monitored less invasively, and clinical decisions are increasingly guided by individual disease biology.
- 15 May 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (5) , e70193
Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12‐year retrospective analysis within NETwerk , an ENETS center of excellence
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant tumor predisposition syndrome in which neuroendocrine tumors (NET) represent a major driver of morbidity and mortality. Timely recognition of MEN1 after NET diagnosis enables syndrome‐specific surveillance and cascade testing, yet real‐world evidence on MEN1 testing implementation in oncology pathways remains limited. The aim of this study was to evaluate MEN1 testing practices and assess concordance with guideline‐based indications and nomogram‐predicted risk. A retrospective cohort study was performed within NETwerk, a Belgian ENETS CoE, with patients MEN1 testing data were extracted from medical records. In patients without a prior MEN1 diagnosis at NET presentation, guideline‐based indications for MEN1 testing were assessed and compared with observed testing. Additionally, nomogram‐predicted MEN1 risk was estimated, using a ≥5% threshold for descriptive risk stratification, and overlap between guideline‐ and nomogram‐based indications was described. In 267 patients without prior MEN1 diagnosis, MEN1 testing was performed in 42 (15.7%), mainly in patients ≤50 years. Including 21 patients with MEN1 diagnosis before NET development, overall MEN1 prevalence was 10.4%. In patients without a prior MEN1 diagnosis at NET presentation, guideline‐based indications showed moderate agreement with observed testing ( κ = 0.50, p < .001) without directional bias toward over‐ or undertesting, with undertesting most evident in MEN1‐suspicious tumor presentations (gastrinoma, early‐onset panNET, thymic NET). Among patients tested despite lacking guideline indications ( n = 20), none had MEN1. Application of the nomogram yielded an exact risk score for 77 patients and a risk score range for the remaining 190 patients due to incomplete phenotyping. In the patients with complete phenotyping, median predicted MEN1 risk was 3.3% (IQR 2.4–4.3). Testing rate increased with higher predicted risk: 85.7% (12/14) for ≥5% underwent testing vs. 23.8% (15/63) for MEN1 testing after NET diagnosis showed moderate alignment with guideline‐based indications and was constrained by incomplete risk capture and phenotyping. Embedding a standardized MEN1 risk checklist and minimal endocrine phenotyping into NET MDT workflows, supported by quantitative risk estimation in selected cases, may improve guideline‐concordant MEN1 detection and downstream benefits for patients and their relatives.
- 15 May 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (5) , e70193
Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12‐year retrospective analysis within NETwerk , an ENETS center of excellence
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant tumor predisposition syndrome in which neuroendocrine tumors (NET) represent a major driver of morbidity and mortality. Timely recognition of MEN1 after NET diagnosis enables syndrome‐specific surveillance and cascade testing, yet real‐world evidence on MEN1 testing implementation in oncology pathways remains limited. The aim of this study was to evaluate MEN1 testing practices and assess concordance with guideline‐based indications and nomogram‐predicted risk. A retrospective cohort study was performed within NETwerk, a Belgian ENETS CoE, with patients MEN1 testing data were extracted from medical records. In patients without a prior MEN1 diagnosis at NET presentation, guideline‐based indications for MEN1 testing were assessed and compared with observed testing. Additionally, nomogram‐predicted MEN1 risk was estimated, using a ≥5% threshold for descriptive risk stratification, and overlap between guideline‐ and nomogram‐based indications was described. In 267 patients without prior MEN1 diagnosis, MEN1 testing was performed in 42 (15.7%), mainly in patients ≤50 years. Including 21 patients with MEN1 diagnosis before NET development, overall MEN1 prevalence was 10.4%. In patients without a prior MEN1 diagnosis at NET presentation, guideline‐based indications showed moderate agreement with observed testing ( κ = 0.50, p < .001) without directional bias toward over‐ or undertesting, with undertesting most evident in MEN1‐suspicious tumor presentations (gastrinoma, early‐onset panNET, thymic NET). Among patients tested despite lacking guideline indications ( n = 20), none had MEN1. Application of the nomogram yielded an exact risk score for 77 patients and a risk score range for the remaining 190 patients due to incomplete phenotyping. In the patients with complete phenotyping, median predicted MEN1 risk was 3.3% (IQR 2.4–4.3). Testing rate increased with higher predicted risk: 85.7% (12/14) for ≥5% underwent testing vs. 23.8% (15/63) for MEN1 testing after NET diagnosis showed moderate alignment with guideline‐based indications and was constrained by incomplete risk capture and phenotyping. Embedding a standardized MEN1 risk checklist and minimal endocrine phenotyping into NET MDT workflows, supported by quantitative risk estimation in selected cases, may improve guideline‐concordant MEN1 detection and downstream benefits for patients and their relatives.
- 2 July 2025
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1370, 344381
Rapid detection of NPY methylation in colorectal cancer using a singlet oxygen-based photoelectrochemical ratiometric bio-platform
- 2 July 2025
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1370, 344381
Rapid detection of NPY methylation in colorectal cancer using a singlet oxygen-based photoelectrochemical ratiometric bio-platform
- 22 November 2023
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 24 (12) , 1833-1851
The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective
Opinion statement Given the considerable heterogeneity in neuroendocrine neoplasms (NENs), it appears unlikely that a sole biomarker exists capable of fully capturing all useful clinical aspects of these tumors. This is reflected in the abundant number of biomarkers presently available for the diagnosis, prognosis, and monitoring of NEN patients. Although assessment of immunohistochemical and radiological markers remains paramount and often obligatory, there has been a notable surge of interest in circulating biomarkers over the years given the numerous benefits associated with liquid biopsies. Currently, the clinic primarily relies on single-analyte assays such as the chromogranin A assay, but these are far from ideal because of limitations such as compromised sensitivity and specificity as well as a lack of standardization. Consequently, the quest for NEN biomarkers continued with the exploration of multianalyte markers, exemplified by the development of the NETest and ctDNA-based analysis. Here, an extensive panel of markers is simultaneously evaluated to identify distinct signatures that could enhance the accuracy of patient diagnosis, prognosis determination, and response to therapy prediction and monitoring. Given the promising results, the development and implementation of these multianalyte markers are expected to usher in a new era of NEN biomarkers in the clinic. In this review, we will outline both clinically implemented and more experimental circulating markers to provide an update on developments in this rapidly evolving field.
- 22 November 2023
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 24 (12) , 1833-1851
The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective
Opinion statement Given the considerable heterogeneity in neuroendocrine neoplasms (NENs), it appears unlikely that a sole biomarker exists capable of fully capturing all useful clinical aspects of these tumors. This is reflected in the abundant number of biomarkers presently available for the diagnosis, prognosis, and monitoring of NEN patients. Although assessment of immunohistochemical and radiological markers remains paramount and often obligatory, there has been a notable surge of interest in circulating biomarkers over the years given the numerous benefits associated with liquid biopsies. Currently, the clinic primarily relies on single-analyte assays such as the chromogranin A assay, but these are far from ideal because of limitations such as compromised sensitivity and specificity as well as a lack of standardization. Consequently, the quest for NEN biomarkers continued with the exploration of multianalyte markers, exemplified by the development of the NETest and ctDNA-based analysis. Here, an extensive panel of markers is simultaneously evaluated to identify distinct signatures that could enhance the accuracy of patient diagnosis, prognosis determination, and response to therapy prediction and monitoring. Given the promising results, the development and implementation of these multianalyte markers are expected to usher in a new era of NEN biomarkers in the clinic. In this review, we will outline both clinically implemented and more experimental circulating markers to provide an update on developments in this rapidly evolving field.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Purpose:As noninvasive biomarkers are an important unmet need for neuroendocrine neoplasms (NEN), biomarker potential of genome-wide molecular profiling of plasma cell-free DNA (cfDNA) was prospectively studied in patients with NEN.Experimental Design:Longitudinal plasma samples were collected from patients with well-differentiated, metastatic gastroenteropancreatic and lung NEN. cfDNA was subjected to shallow whole-genome sequencing to detect genome-wide copy-number alterations (CNA) and estimate circulating tumor DNA (ctDNA) fraction, and correlated to clinicopathologic and survival data. To differentiate pancreatic NENs (PNEN) from pancreatic adenocarcinomas (PAAD) using liquid biopsies, a classification model was trained using tissue-based CNAs and validated in cfDNA.Results:One hundred and ninety-five cfDNA samples from 43 patients with NEN were compared with healthy control cfDNA (N = 100). Plasma samples from patients with PNEN (N = 21) were used for comparison with publicly available PNEN tissue (N = 98), PAAD tissue (N = 109), and PAAD cfDNA (N = 96). Thirty percent of the NEN cfDNA samples contained ctDNA and 44% of the patients had at least one ctDNA-positive (ctDNA+) sample. CNAs detected in cfDNA were highly specific for NENs and the classification model could distinguish PAAD and PNEN cfDNA samples with a sensitivity, specificity, and AUC of 62%, 86%, and 79%, respectively. ctDNA-positivity was associated with higher World Health Organization (WHO) grade, primary tumor location, and higher chromogranin A and neuron-specific enolase values. Overall survival was significantly worse for ctDNA+ patients and increased ctDNA fractions were associated with poorer progression-free survival.Conclusions:Sequential genome-wide profiling of plasma cfDNA is a novel, noninvasive biomarker with high specificity for diagnosis, prognosis, and follow-up in metastatic NENs.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Purpose:As noninvasive biomarkers are an important unmet need for neuroendocrine neoplasms (NEN), biomarker potential of genome-wide molecular profiling of plasma cell-free DNA (cfDNA) was prospectively studied in patients with NEN.Experimental Design:Longitudinal plasma samples were collected from patients with well-differentiated, metastatic gastroenteropancreatic and lung NEN. cfDNA was subjected to shallow whole-genome sequencing to detect genome-wide copy-number alterations (CNA) and estimate circulating tumor DNA (ctDNA) fraction, and correlated to clinicopathologic and survival data. To differentiate pancreatic NENs (PNEN) from pancreatic adenocarcinomas (PAAD) using liquid biopsies, a classification model was trained using tissue-based CNAs and validated in cfDNA.Results:One hundred and ninety-five cfDNA samples from 43 patients with NEN were compared with healthy control cfDNA (N = 100). Plasma samples from patients with PNEN (N = 21) were used for comparison with publicly available PNEN tissue (N = 98), PAAD tissue (N = 109), and PAAD cfDNA (N = 96). Thirty percent of the NEN cfDNA samples contained ctDNA and 44% of the patients had at least one ctDNA-positive (ctDNA+) sample. CNAs detected in cfDNA were highly specific for NENs and the classification model could distinguish PAAD and PNEN cfDNA samples with a sensitivity, specificity, and AUC of 62%, 86%, and 79%, respectively. ctDNA-positivity was associated with higher World Health Organization (WHO) grade, primary tumor location, and higher chromogranin A and neuron-specific enolase values. Overall survival was significantly worse for ctDNA+ patients and increased ctDNA fractions were associated with poorer progression-free survival.Conclusions:Sequential genome-wide profiling of plasma cfDNA is a novel, noninvasive biomarker with high specificity for diagnosis, prognosis, and follow-up in metastatic NENs.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Purpose:As noninvasive biomarkers are an important unmet need for neuroendocrine neoplasms (NEN), biomarker potential of genome-wide molecular profiling of plasma cell-free DNA (cfDNA) was prospectively studied in patients with NEN.Experimental Design:Longitudinal plasma samples were collected from patients with well-differentiated, metastatic gastroenteropancreatic and lung NEN. cfDNA was subjected to shallow whole-genome sequencing to detect genome-wide copy-number alterations (CNA) and estimate circulating tumor DNA (ctDNA) fraction, and correlated to clinicopathologic and survival data. To differentiate pancreatic NENs (PNEN) from pancreatic adenocarcinomas (PAAD) using liquid biopsies, a classification model was trained using tissue-based CNAs and validated in cfDNA.Results:One hundred and ninety-five cfDNA samples from 43 patients with NEN were compared with healthy control cfDNA (N = 100). Plasma samples from patients with PNEN (N = 21) were used for comparison with publicly available PNEN tissue (N = 98), PAAD tissue (N = 109), and PAAD cfDNA (N = 96). Thirty percent of the NEN cfDNA samples contained ctDNA and 44% of the patients had at least one ctDNA-positive (ctDNA+) sample. CNAs detected in cfDNA were highly specific for NENs and the classification model could distinguish PAAD and PNEN cfDNA samples with a sensitivity, specificity, and AUC of 62%, 86%, and 79%, respectively. ctDNA-positivity was associated with higher World Health Organization (WHO) grade, primary tumor location, and higher chromogranin A and neuron-specific enolase values. Overall survival was significantly worse for ctDNA+ patients and increased ctDNA fractions were associated with poorer progression-free survival.Conclusions:Sequential genome-wide profiling of plasma cfDNA is a novel, noninvasive biomarker with high specificity for diagnosis, prognosis, and follow-up in metastatic NENs.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Purpose:As noninvasive biomarkers are an important unmet need for neuroendocrine neoplasms (NEN), biomarker potential of genome-wide molecular profiling of plasma cell-free DNA (cfDNA) was prospectively studied in patients with NEN.Experimental Design:Longitudinal plasma samples were collected from patients with well-differentiated, metastatic gastroenteropancreatic and lung NEN. cfDNA was subjected to shallow whole-genome sequencing to detect genome-wide copy-number alterations (CNA) and estimate circulating tumor DNA (ctDNA) fraction, and correlated to clinicopathologic and survival data. To differentiate pancreatic NENs (PNEN) from pancreatic adenocarcinomas (PAAD) using liquid biopsies, a classification model was trained using tissue-based CNAs and validated in cfDNA.Results:One hundred and ninety-five cfDNA samples from 43 patients with NEN were compared with healthy control cfDNA (N = 100). Plasma samples from patients with PNEN (N = 21) were used for comparison with publicly available PNEN tissue (N = 98), PAAD tissue (N = 109), and PAAD cfDNA (N = 96). Thirty percent of the NEN cfDNA samples contained ctDNA and 44% of the patients had at least one ctDNA-positive (ctDNA+) sample. CNAs detected in cfDNA were highly specific for NENs and the classification model could distinguish PAAD and PNEN cfDNA samples with a sensitivity, specificity, and AUC of 62%, 86%, and 79%, respectively. ctDNA-positivity was associated with higher World Health Organization (WHO) grade, primary tumor location, and higher chromogranin A and neuron-specific enolase values. Overall survival was significantly worse for ctDNA+ patients and increased ctDNA fractions were associated with poorer progression-free survival.Conclusions:Sequential genome-wide profiling of plasma cfDNA is a novel, noninvasive biomarker with high specificity for diagnosis, prognosis, and follow-up in metastatic NENs.